New Findings on Carcinomas Described by Investigators at Oregon Health & Science University (OHSU) [Adjuvant Everolimus After Surgery for Renal Cell Carcinoma (Everest): a Double-blind, Placebo-controlled, Randomised, Phase 3 Trial].

A recent study conducted by researchers at Oregon Health & Science University (OHSU) evaluated the effectiveness of the drug everolimus in preventing disease relapse in patients who underwent surgery for renal cell carcinoma. The study involved 1,545 patients and found that everolimus did not significantly improve recurrence-free survival compared to a placebo. However, in the very-high-risk group, everolimus did show a longer recurrence-free survival. The study concludes that these results do not support the adjuvant use of everolimus for renal cell carcinoma after surgery. Funding for the research was provided by various organizations including the US National Institutes of Health and Novartis Pharmaceuticals Corporation. [Extracted from the article]